Abstract: Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, baloxavir and derivatives thereof, and baloxavir marboxil and derivatives thereof, and protein (e.g., antibody) drug conjugates thereof.

Abstract: Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Abstract: Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

Abstract: Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, baloxavir and derivatives thereof, and baloxavir marboxil and derivatives thereof, and protein (e.g., antibody) drug conjugates thereof.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Abstract: Non-human animal cells and non-human animals comprising a humanized ACE2 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized ACE2 locus express a human ACE2 protein or a chimeric ACE2 protein, fragments of which are from human ACE2. Methods are also provided for using such non-human animals comprising a humanized ACE2 locus to assess in vivo ACE2 activity, e.g., coronavirus infection and/or the treatment or prevention thereof.

Abstract: The disclosure provides recombinant vesicular stomatitis vims (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike (S) glycoprotein, or a fragment or a derivative thereof, as well as compositions, vaccines, kits, and methods for using the recombinant VSV particles. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are for the treatment or prevention of a disease or disorder in a subject infected with SARS-CoV-2. In certain embodiments, the disease or disorder is COVID-19.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Abstract: Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, baloxavir and derivatives thereof, and baloxavir marboxil and derivatives thereof, and protein (e.g., antibody) drug conjugates thereof.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections or influenza virus infections).

Abstract: Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).